Table 1.

Characteristics of melanoma cell lines

Cell lineBRAF or NRAS mutational statusOther oncogenic events or tumor-suppressor deletionsSensitive (S) or resistant (R) to vemurafeniba
M285Wild-type (36)R
M229BRAF V600EMITF amplificationS (34, 35, 45)
AKT1 amplification
PTEN heterozygous
M233BRAF V600EAKT1 amplificationR (35)
CCND1 amplification
EGFR amplification
CDKN2A heterozygous
PTEN heterozygous
M249BRAF V600EMITF amplificationS (34, 35, 45)
AKT2 amplification
PTEN homozygous
M263BRAF V600ECDKN2A heterozygousR (34, 35)
M308BRAF V600EMITF amplificationR (35)
AKT2 amplification
EGFR amplification
CDKN2A homozygous
M370BRAF V600ER (34)
M395BRAF V600ES (34, 45)
M417BRAF V600EABL1 E255K, Y253HR
EGFR P753S
M202NRAS Q61LEGFR amplificationR (35)
CDKN2A homozygous
M408NRAS Q61KR
M376BRAFV600E/NRAS Q61KR (34)
  • aSensitive, <1 μmol/L; resistant, >1 μmol/L.